PLx Pharma Proposes “GI-Safer” OTC Aspirin In New Drug Application
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm files a rare new drug application for an OTC product, a formulation of aspirin and phosphatidylcholine designed to be more tolerable to the gastrointestinal tract. The involvement of OTC veterans Peter Mann and Michael Valentino on PLx’s board suggests strong market potential.
You may also be interested in...
PLx Pharma Saturates Health Care Providers With Marketing For Liquid-Filled Vazalore Aspirin
PLx says Vazalore, only liquid-filled OTC aspirin in the US, had strong sales growth since launch in 30,000 stores. It plans second phase of rollout and promotions to expand outreach to cardiologists and patients.
Prestige Brands Makes "Seismic Shift" To OTC With Blacksmith Acquisition
On the eve of Blacksmith Brands' one-year anniversary, co-founder and CEO Peter Mann fulfills his promise to cash in on the startup in a $190 million sale to Prestige Brands Holdings, which Mann also helped launch
FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule
FDA's final rule for OTC products containing acetaminophen or nonsteroidal anti-inflammatory drugs requires warnings and revisions that go beyond changes the agency proposed in a 2006 tentative final rule